High PLA2G2A expression was also associated with poor prognosis in colon cancer patients harboring BRAF mutations, suggesting its potential as both a prognostic biomarker and a novel immunotherapy target [80]. This evidence concerns the gene PLA2G2A and colonic neoplasm.